Article Per Year (5 Year)
p-Index From 2020 - 2025
0.751
P-Index
This Author published in this journals
All Journal Jurnal Ilmiah Jophus: Journal of Pharmacy UMUS PCJN Pharmaceutical and Clinical Journal of Nusantara Jurnal An-Najat: Jurnal Ilmu Farmasi dan Kesehatan Jurnal Farmasi Galenika
Ria Indah Pratami
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Chemistry Dentistry Health Professions Immunology & microbiology Medicine & Pharmacology Neuroscience Nursing Public Health Veterinary

Published : 4 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 4 Documents
Search

 1 
Ilmu Kefarmasian Dalam Prespektif Islam dan Kemuhammadiyaan Ria Indah Pratami; Oman Fathurohman sw
An-Najat Vol. 2 No. 3 (2024): AGUSTUS - An-Najat: Jurnal Ilmu Farmasi dan Kesehatan
Publisher : STIKes Ibnu Sina Ajibarang

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.59841/an-najat.v2i3.1484

Abstract

The pharmaceutical world today has developed very quickly, and this development has seen a shift in focus to current products. The principles of treatment that contain high and noble values ​​emerged from the revelation of the Koran and Islamic teachings conveyed by the Prophet Muhammad. This research aims to analyze pharmaceutical science from an Islamic and Muhammadiyah perspective, with a focus on developing a pharmaceutical practice model that is based on the ethical and moral values ​​taught by Islam. The method used is literature research with data sources from published research. Literature review involves reading books, journals, and other publications related to the research topic in order to write about the subject. Based on research findings, pharmaceutical practitioners and health institutions apply Islamic and Muhammadiyah principles in their practice, thereby making a significant contribution to improving the quality of health services and welfare of the people through an ethical, moral and sustainable approach in accordance with Islamic teachings and Muhammadiyah values
Pharmacogenomic and Bioinformatic Insights into ACE Gene Variants and Their Influence on ACE Inhibitor Response in Hypertension Amukti, Danang Prasetyaning; Ria Indah Pratami; Ismyama, Dian Farida; Puspitasari, Ade; Herlina, Tetie
PCJN: Pharmaceutical and Clinical Journal of Nusantara Vol. 3 No. 02 (2025): PCJN: Pharmaceutical and Clinical Journal of Nusantara
Publisher : CV. Nusantara Scientific Medical

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.58549/pcjn.v3i02.113

Abstract

Response to angiotensin-converting enzyme inhibitors (ACEIs)-based antihypertensive therapy varies between individuals, which is largely influenced by genetic factors. The ACE gene has several polymorphisms that can affect enzyme levels and therapeutic efficacy. This study aims to explore the relationship between genetic variations in the ACE gene and response to captopril, lisinopril, ramipril, and enalapril in hypertensive patients. This study used a bioinformatics and pharmacogenomics approach by analyzing data from PharmGKB, Ensembl, and GTEx Portal. Genetic polymorphisms were analyzed to evaluate their association with ACEI efficacy using a descriptive statistical approach. Results: Four single nucleotide polymorphisms (SNPs) in the ACE gene were found to be associated with response to ACEI. Variants rs4291 and rs1799752 were associated with captopril efficacy, where the AA genotype showed a decrease in the severity of renal failure. The rs1799752 variant was also associated with lisinopril and enalapril, with the DD genotype providing greater blood pressure reduction. In addition, rs4359 and rs4344 were correlated with the efficacy of ramipril, especially in the CC+TT and AA+GG genotypes. Genetic variation in the ACE gene plays a role in determining the response to ACEI therapy. Pharmacogenetic approaches have the potential to improve the efficacy and safety of antihypertensive treatment.
ANALISIS EKSPRESI MMP1 PADA KARSINOMA PAYUDARA INVASIF DENGAN BIOINFORMATIKA MELALUI UALCAN: BIOMARKER PROGNOSTIK POTENSIAL: Analysis of MMP1 Expression in Invasive Breast Carcinoma with Bioinformatics via UALCAN : A Potential Prognostic Biomarker Danang Prasetyaning Amukti; Ria Indah Pratami
Jurnal Ilmiah JOPHUS : Journal Of Pharmacy UMUS Vol. 7 No. 1 (2025): Agustus
Publisher : Program Studi Farmasi, Universitas Muhadi Setiabudi

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.46772/jophus.v7i1.1778

Abstract

Pendahuluan: Kanker payudara invasif (BRCA) merupakan penyebab utama kematian kanker pada wanita global. Matrix Metalloproteinase-1 (MMP1), enzim pemecah matriks ekstraseluler, diduga berperan dalam invasi dan metastasis BRCA. Penelitian ini bertujuan menganalisis potensi MMP1 sebagai biomarker prognostik BRCA menggunakan pendekatan bioinformatika. Metode: Studi berbasis data TCGA ini menggunakan platform UALCAN untuk menganalisis ekspresi MMP1, metilasi promotor, dan hubungannya dengan parameter klinis. Analisis statistik meliputi uji-t, ANOVA, dan kurva Kaplan-Meier dengan uji log-rank (signifikansi p<0,05). Hasil: Ekspresi MMP1 pada jaringan tumor 5 kali lebih tinggi daripada normal (p<0,001), didukung hipometilasi promotor. Pasien dengan ekspresi tinggi MMP1 menunjukkan survival lebih buruk (p=0,0042). Variasi signifikan terlihat berdasarkan ras (terburuk pada African-American), status menopause (terburuk post-menopause), dan subtipe molekuler (HER2+ dan triple-negatif). Kesimpulan: MMP1 terbukti sebagai biomarker prognostik potensial untuk BRCA dengan implikasi klinis dalam stratifikasi risiko dan terapi target. Temuan ini mendorong penelitian lanjutan untuk validasi klinis dan pengembangan terapi spesifik.
Analisis Bioinformatika Ekspresi MIER3 sebagai Biomarker Potensial dan Target Terapeutik pada Kanker Esofagus Amukti, Danang; Ria Indah Pratami
JURNAL FARMASI GALENIKA Vol 12 No 2 (2025): Jurnal Farmasi Galenika
Publisher : Universitas Bhakti Kencana

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.70410/jfg.v12i2.389

Abstract

Esophageal cancer (ESCA) is one of the cancers with high mortality rates worldwide. Determination of prognostic biomarkers that can predict patient survival is very important to support more effective therapy management. The MIER3 gene has been reported to play a role in the regulation of gene expression and cell proliferation pathways, but its role in ESCA is still not fully understood. MIER3 gene expression data and patient clinical information were obtained from the UALCAN database based on TCGA. Survival analysis was performed using the Kaplan-Meier method to evaluate the effect of MIER3 expression levels on ESCA patient survival. Further analysis was performed by combining MIER3 expression with clinical variables such as tumor grade, race, gender, and weight status. MIER3 expression was significantly higher in tumor tissue than in normal tissue. Kaplan-Meier showed that patients with high MIER3 expression had significantly lower survival than the low expression group (p = 0.00013). The combination of MIER3 expression and clinical factors such as gender (p = 0.00046), race (p = 0.0095), and body weight (p = 0.008) also showed a prognostic relationship to survival. MIER3 has the potential as a prognostic biomarker in esophageal cancer. High MIER3 expression correlates with poor prognosis, especially when combined with certain clinical factors. These findings suggest that MIER3 may play a role in tumor progression through molecular mechanisms involving activation of proliferative pathways and inhibition of apoptotic pathways, and support the development of gene expression-based targeted therapy.
Co-Authors Amukti, Danang Danang Prasetyaning Amukti Herlina, Tetie Ismyama, Dian Farida Oman Fathurohman sw Puspitasari, Ade